Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02601560 · ClinicalTrials.gov registry record · Phase 2

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

A Phase 2 study of Coronary Artery Disease, sponsored by MedImmune.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
8
Study locations

NCT02601560 is a Phase 2 study of Coronary Artery Disease that has completed, run by MedImmune. The registered enrollment target is 48 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02601560, a Phase 2 study of Coronary Artery Disease, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
8
Study locations

Study Summary

This is a Phase 2a randomized, double-blind (subject/investigator blinded, MedImmune unblinded), placebo-controlled, dose-escalation study to evaluate the safety, PK/PD, and immunogenicity of single IV and SC MEDI6012 doses in adult subjects with stable CAD.

Conditions Studied

Coronary Artery Disease

Interventions

  • BIOLOGICAL MEDI6012
  • BIOLOGICAL Placebo SC
  • BIOLOGICAL Placebo IV

Study Locations (8)

Florida

  • Research Site - Jacksonville
  • Research Site - Port Orange

North Carolina

  • Research Site - Durham
  • Research Site - Raleigh

Alabama

  • Research Site - Anniston

Ohio

  • Research Site - Cincinnati

Texas

  • Research Site - San Antonio

Virginia

  • Research Site - Falls Church

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2015-12-03
Est. Completion 2016-11-03
Phase Phase 2

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02601560

The ClinicalTrials.gov registry entry for NCT02601560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (96% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 3 interventions - of which MEDI6012 is the first listed.

NCT02601560 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, North Carolina, Alabama.

Frequently Asked Questions

What is clinical trial NCT02601560 about?

NCT02601560 is a clinical study titled "To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease". This is a Phase 2a randomized, double-blind (subject/investigator blinded, MedImmune unblinded), placebo-controlled, dose-escalation study to evaluate the safety, PK/PD, and immunogenicity of single IV and SC MEDI6012 doses in adult subjects with stable CAD.

What is the current status of trial NCT02601560?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-12-03. Estimated completion is 2016-11-03.

What conditions does trial NCT02601560 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT02601560?

The interventions under investigation include: MEDI6012 (BIOLOGICAL), Placebo SC (BIOLOGICAL), Placebo IV (BIOLOGICAL).

Who is sponsoring clinical trial NCT02601560?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02601560 being conducted?

This trial has 8 study locations across Alabama, Florida, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.